Long-Term Safety and Efficacy of a Novel Iron-Containing Phosphate Binder, JTT-751, in Patients Receiving Hemodialysis

Journal of Renal Nutrition

Volumn 24, Issue 4, 2014, Pages 261-267

  Yokoyama, Keitaro ^a   Akiba, Takashi ^b   Fukagawa, Masafumi ^c   Nakayama, Masaaki ^d   Sawada, Kenichi ^e   Kumagai, Yuji ^f   Chertow, Glenn M ^g   Hirakata, Hideki ^h  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^e AKITA UNIVERSITY   (Japan)

^f KITASATO UNIVERSITY HOSPITAL   (Japan)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h FUKUOKA RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; CALCIUM; FERRIC CITRATE; FERRIC ION; FERRITIN; IRON; PARATHYROID HORMONE; PHOSPHATE; PHOSPHORUS;

AGED; BIOASSAY; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; GASTROINTESTINAL DISEASES; HUMAN; HYPERPHOSPHATEMIA; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; RENAL REPLACEMENT THERAPY;

AGED; CALCIUM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; FEMALE; FERRIC COMPOUNDS; FERRITINS; GASTROINTESTINAL DISEASES; HEMATINICS; HUMANS; HYPERPHOSPHATEMIA; IRON; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHATES; PHOSPHORUS; RENAL DIALYSIS;

EID: 84902536872     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2014.03.006     Document Type: Article

References (25)

1. Moe S., Drüeke T., Cunningham J., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006, 69:1945-1953.
2. Block G.A., Hulbert-Shearon T.E., Levin N.W., et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998, 31:607-617.
3. Braun J., Oldendorf M., Moshage W., et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996, 27:394-401.
4. Sarnak M.J. Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003, 41(5 Suppl):11-17.
5. Fukagawa M., Yokoyama K., Koiwa F., et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 2013, 17:247-288.
6. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009, 113:S1-S130. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group.
7. Nagina A. Phosphate binders in CKD: past, present, and future. J Indian Acad Clin Med 2009, 10:43-45.
8. Sinsakul M., Sika M., Koury M., et al. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract 2012, 121:c25-c29.
9. Iida A., Kemmochi Y., Kakimoto K., et al. Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification. Am J Nephrol 2013, 37:346-358.
10. Yokoyama K., Hirakata H., Akiba T., et al. Effect of oral JTT-751 (ferric citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol 2012, 36:478-487.
11. Payne R.B., Carver M.E., Morgan D.B. Interpretation of serum total calcium: effects of adjustment for albumin concentration on frequency of abnormal values and on detection of change in the individual. J Clin Pathol 1979, 32:56-60.
12. Aljima P., Bommer J., Canaud B., et al. Practical guidelines for the use of NESP in treating renal anaemia. Nephrol Dial Transpl 2001, 16(Suppl 3):22-28.
13. Carrera F., Lok C.E., de Francisco A., et al. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transpl 2010, 25:4009-4017.
14. John M.J., Jaison V., Jain K., et al. Erythropoietin use and abuse. Indian J Endocrinol Metab 2012, 16:220-227.
15. Yokoyama K., Akiba T., Fukagawa M., et al. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transpl 2013, [published online ahead of print December 26 2013], Accessed January 29, 2014. http://www.ncbi.nlm.nih.gov/pubmed/24376274.
16. Block G.A., Klassen P.S., Lazarus J.M., et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004, 15:2208-2218.
17. Chertow G.M., Raggi P., Chasan-Taber S., et al. Determinants of progressive vascular calcification in hemodialysis patients. Nephrol Dial Transpl 2004, 19:1489-1496.
18. Hutchison A.J., Barnett M.E., Krause R., et al. long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract 2008, 110:c15-c23. SPD405-309 lanthanum study group.
19. Silverstein S.B., Rodgers G.M. Parenteral iron therapy options. Am J Hematol 2004, 76:74-78.
20. Bailie G.R., Larkina M., Goodkin D.A., et al. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transpl 2013, 28:2570-2579.
21. Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol 2008, 15:169-175.
22. Kemna E.H., Tjalsma H., Willems H.L., et al. Hepcidin: from discovery to differential diagnosis. Haetmatologica 2008, 93:90-97.
23. Ferrari P., Kulkarni H., Dheda S., et al. Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease. Clin J Am Soc Nephrol 2011, 6:77-83.
24. Lim P.S., Wei Y.H., Yu Y.L., et al. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transpl 1999, 14:2680-2687.
25. Anraku M., Kitamura K., Shintomo R., et al. Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: a pilot study. Clin Biochem 2008, 41:1168-1174.